IFNB1 and myeloid sarcoma: Strikingly, proliferation of T cells isolated from MS patients treated with IFN-β, regardless of which preparation of IFN-β was used, were suppressed by activated Treg from independent third donors (Figure 4A, lower panel), suggesting that this immune-modulatory therapy at least partially restored Treg sensitivity of T cells in MS patients.